MeiraGTx Holdings plc is a gene therapy company focused on developing treatments for serious diseases such as ocular, degenerative, and neurodegenerative diseases. They have programs in clinical development and preclinical programs to treat various illnesses such as Parkinson's disease and X-Linked Retinitis Pigmentosa. MeiraGTx also has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology.